Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients.
about
Potentially functional variants in the core nucleotide excision repair genes predict survival in Japanese gastric cancer patients.Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients.A functional analysis of G23A polymorphism and the alternative splicing in the expression of the XPA gene.An association between DNA repair gene polymorphisms and survival in patients with resected non-small cell lung cancer.Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer.Variants in nucleotide excision repair core genes and susceptibility to recurrence of squamous cell carcinoma of the oropharynx.Association between ERCC1 and XPA expression and polymorphisms and the response to cisplatin in testicular germ cell tumours.Genetic variants in the fibroblast growth factor pathway as potential markers of ovarian cancer risk, therapeutic response, and clinical outcomeFunctional Analysis of SNPs in the ERCC5 Promoter in Advanced Colorectal Cancer Patients Treated With Oxaliplatin-Based ChemotherapyExplorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair arrayPharmaco(epi)genomics in ovarian cancer.Genetic variants in telomere-maintenance genes are associated with ovarian cancer risk and outcome.Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the Ovarian Cancer Association Consortium (OCAC).Genetic markers for prediction of treatment outcomes in ovarian cancer.Single nucleotide polymorphisms in DNA repair genes and putative cancer risk.Chinese C allele carriers of the ERCC5 rs1047768 polymorphism are more sensitive to platinum-based chemotherapy: a meta-analysis.
P2860
Q31170960-584DB532-97FD-4751-AB36-838C0EE55E3AQ33386412-54DCC7CE-565F-4647-9CFB-E24A26AA4E3CQ33701903-980F9B74-FEE6-4FEA-9F6F-A6888D5A938CQ33781302-5DAC864D-74D0-40DC-AA42-FCA5631651D6Q33959550-2B223405-C97A-4E12-8DBC-A850D08DA063Q34555379-745A2408-17CF-47AE-8F93-4EC33FDAE29AQ34786179-1DA20BD6-DCA5-40DB-8855-239BACB11B56Q35623040-C8A2EF4D-12D6-4F4E-95AB-5D0A15084AB8Q36993563-B92761D0-E0DC-4F2A-AFCA-36A678DAFA97Q37287450-A66BDF73-A868-456F-A996-10845B4ED161Q37346198-361851A4-1D16-4C70-B622-0D96DF3FF353Q37662864-5E963D6F-943A-42B6-8F11-AFF969680F7CQ37996440-62A013BF-3AC1-4D3B-AF0A-E53360556492Q38227080-93692FDF-6135-4963-B5F1-522DC9131C66Q38873757-4E9DC80C-2953-4815-B289-1FE272DE92BFQ49359901-2475B122-51A7-4E17-90C8-49518C8366A9
P2860
Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients.
description
2007 nî lūn-bûn
@nan
2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Moving toward individualized t ...... ty in ovarian cancer patients.
@ast
Moving toward individualized t ...... ty in ovarian cancer patients.
@en
Moving toward individualized t ...... ty in ovarian cancer patients.
@nl
type
label
Moving toward individualized t ...... ty in ovarian cancer patients.
@ast
Moving toward individualized t ...... ty in ovarian cancer patients.
@en
Moving toward individualized t ...... ty in ovarian cancer patients.
@nl
prefLabel
Moving toward individualized t ...... ty in ovarian cancer patients.
@ast
Moving toward individualized t ...... ty in ovarian cancer patients.
@en
Moving toward individualized t ...... ty in ovarian cancer patients.
@nl
P2093
P1433
P1476
Moving toward individualized t ...... ty in ovarian cancer patients.
@en
P2093
Anne-Therese Vlastos
Dong Liang
J Salvador Saldivar
Karen H Lu
Maosheng Huang
P304
P356
10.1016/J.YGYNO.2007.07.024
P407
P433
P577
2007-09-06T00:00:00Z